Voya Investment Management LLC Sells 1,627 Shares of Viridian Therapeutics, Inc. $VRDN

Voya Investment Management LLC cut its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 7.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,770 shares of the company’s stock after selling 1,627 shares during the period. Voya Investment Management LLC’s holdings in Viridian Therapeutics were worth $266,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Amalgamated Bank increased its holdings in shares of Viridian Therapeutics by 49.7% in the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after acquiring an additional 840 shares during the period. GAMMA Investing LLC lifted its position in Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after acquiring an additional 8,214 shares during the period. EntryPoint Capital LLC acquired a new stake in Viridian Therapeutics during the 1st quarter worth about $185,000. Quantbot Technologies LP lifted its position in Viridian Therapeutics by 146.4% during the 1st quarter. Quantbot Technologies LP now owns 21,131 shares of the company’s stock worth $285,000 after acquiring an additional 12,556 shares during the period. Finally, Knott David M Jr lifted its holdings in shares of Viridian Therapeutics by 20.0% in the 1st quarter. Knott David M Jr now owns 30,000 shares of the company’s stock valued at $404,000 after buying an additional 5,000 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on VRDN. Needham & Company LLC decreased their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. The Goldman Sachs Group upped their price target on Viridian Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. Wells Fargo & Company cut their price objective on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Oppenheimer upped their price target on Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Finally, Jefferies Financial Group started coverage on Viridian Therapeutics in a research report on Monday, August 25th. They issued a “buy” rating and a $44.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.88.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $21.61 on Tuesday. The firm has a market capitalization of $1.76 billion, a PE ratio of -5.64 and a beta of 0.53. The business’s fifty day moving average price is $18.44 and its 200 day moving average price is $15.64. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.01 and a quick ratio of 11.01. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, meeting the consensus estimate of ($1.00). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.Viridian Therapeutics’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.81) earnings per share. On average, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.